MalayalamNewsableKannadaKannadaPrabhaTeluguTamilBanglaHindiMarathiMyNation
Add Preferred SourceGoogle-icon
  • Facebook
  • Twitter
  • whatsapp
  • YT video
  • insta
  • Latest News
  • India
  • World
  • Business
  • Markets
  • Sports
  • Entertainment
  • Technology
  • Auto
  • Lifestyle
  • Home
  • India
  • Top Stories
  • Covaxin is not a backup. We don't deserve backlash: Bharat Biotech MD Krishna Ella

Covaxin is not a backup. We don't deserve backlash: Bharat Biotech MD Krishna Ella

Taking on naysayers, Bharat Biotech MD Krishna Ella said: "Now that the vaccine is being politicized, I want to state very clearly that none of my family members is associated with any political party."

3 Min read
Asianet Newsable English
Published : Jan 04 2021, 07:30 PM IST
Share this Photo Gallery
  • FB
  • TW
  • Linkdin
  • Whatsapp
  • GNFollow Us
14
<p>Bharat Biotech MD Krishna Ella has sought to dispel speculation regarding the company's Coronavirus vaccine Covaxin's efficacy.&nbsp;<br />&nbsp;</p><p>There have been aspersions cast from members of the scientific community and Opposition leaders over the vaccine been granted Emergency Use Authorisation despite lack of Phase 3 trial data.<br />&nbsp;</p><p>Defending the vaccine, the Bharat Biotech MD said: "We are not just conducting clinical trials in India. We have done clinical trials more than 12 countries including the UK. We are doing clinical trials in Pakistan, Nepal, Bangladesh &amp; other countries. We are not just an Indian company, we are truly a global company.</p>

<p>Bharat Biotech MD Krishna Ella has sought to dispel speculation regarding the company's Coronavirus vaccine Covaxin's efficacy.&nbsp;<br />&nbsp;</p><p>There have been aspersions cast from members of the scientific community and Opposition leaders over the vaccine been granted Emergency Use Authorisation despite lack of Phase 3 trial data.<br />&nbsp;</p><p>Defending the vaccine, the Bharat Biotech MD said: "We are not just conducting clinical trials in India. We have done clinical trials more than 12 countries including the UK. We are doing clinical trials in Pakistan, Nepal, Bangladesh &amp; other countries. We are not just an Indian company, we are truly a global company.</p>

Bharat Biotech MD Krishna Ella has sought to dispel speculation regarding the company's Coronavirus vaccine Covaxin's efficacy. 
 

There have been aspersions cast from members of the scientific community and Opposition leaders over the vaccine been granted Emergency Use Authorisation despite lack of Phase 3 trial data.
 

Defending the vaccine, the Bharat Biotech MD said: "We are not just conducting clinical trials in India. We have done clinical trials more than 12 countries including the UK. We are doing clinical trials in Pakistan, Nepal, Bangladesh & other countries. We are not just an Indian company, we are truly a global company.

Add Asianet Newsable as a Preferred SourcegooglePreferred
24
<p>Taking on naysayers, Krishna Ella said: "Now that the vaccine is being politicized, I want to state very clearly that none of my family members is associated with any political party."<br />&nbsp;</p><p>"We are not a company without experience in vaccines. We have tremendous experience in vaccines. We are touching 123 countries. We are the only company that has got such extensive experience &amp; extensive publication in review journals," he said.<br />&nbsp;</p><p>Krishna Ella said: "Many people just gossiping, it's just a backlash against Indian companies. That is not right for us. We don't deserve that. Merck's Ebola vaccine never completed a human clinical trial at all but WHO gave emergency authorization for Liberia &amp; Guinea. Even the US government says emergency authorization can be given if a company has good immunization data. Merck's Ebola vaccine got authorization for emergency use even before completion of the phase-3 trial. Johnson &amp; Johnson did trials on 87 people and got an emergency licence."&nbsp;</p><p>&nbsp;</p>

<p>Taking on naysayers, Krishna Ella said: "Now that the vaccine is being politicized, I want to state very clearly that none of my family members is associated with any political party."<br />&nbsp;</p><p>"We are not a company without experience in vaccines. We have tremendous experience in vaccines. We are touching 123 countries. We are the only company that has got such extensive experience &amp; extensive publication in review journals," he said.<br />&nbsp;</p><p>Krishna Ella said: "Many people just gossiping, it's just a backlash against Indian companies. That is not right for us. We don't deserve that. Merck's Ebola vaccine never completed a human clinical trial at all but WHO gave emergency authorization for Liberia &amp; Guinea. Even the US government says emergency authorization can be given if a company has good immunization data. Merck's Ebola vaccine got authorization for emergency use even before completion of the phase-3 trial. Johnson &amp; Johnson did trials on 87 people and got an emergency licence."&nbsp;</p><p>&nbsp;</p>

Taking on naysayers, Krishna Ella said: "Now that the vaccine is being politicized, I want to state very clearly that none of my family members is associated with any political party."
 

"We are not a company without experience in vaccines. We have tremendous experience in vaccines. We are touching 123 countries. We are the only company that has got such extensive experience & extensive publication in review journals," he said.
 

Krishna Ella said: "Many people just gossiping, it's just a backlash against Indian companies. That is not right for us. We don't deserve that. Merck's Ebola vaccine never completed a human clinical trial at all but WHO gave emergency authorization for Liberia & Guinea. Even the US government says emergency authorization can be given if a company has good immunization data. Merck's Ebola vaccine got authorization for emergency use even before completion of the phase-3 trial. Johnson & Johnson did trials on 87 people and got an emergency licence." 

 

34
<p>Slamming detractors for claiming that the company was not being transparent with regard to the vaccine data, the Bharat Biotech MD said: "I think people should have the patience to read on the internet &amp; how many articles we have published. More than 70 articles have been published in various international journals."<br />&nbsp;</p><p>He also rejected reports that Covaxin was a "back-up" vaccine.&nbsp;<br />&nbsp;</p><p>"It is a vaccine. It is not a backup. People should be responsible before making such statements," Krishna Ella said.</p>

<p>Slamming detractors for claiming that the company was not being transparent with regard to the vaccine data, the Bharat Biotech MD said: "I think people should have the patience to read on the internet &amp; how many articles we have published. More than 70 articles have been published in various international journals."<br />&nbsp;</p><p>He also rejected reports that Covaxin was a "back-up" vaccine.&nbsp;<br />&nbsp;</p><p>"It is a vaccine. It is not a backup. People should be responsible before making such statements," Krishna Ella said.</p>

Slamming detractors for claiming that the company was not being transparent with regard to the vaccine data, the Bharat Biotech MD said: "I think people should have the patience to read on the internet & how many articles we have published. More than 70 articles have been published in various international journals."
 

He also rejected reports that Covaxin was a "back-up" vaccine. 
 

"It is a vaccine. It is not a backup. People should be responsible before making such statements," Krishna Ella said.

44
<p>The Biotech MD said that the company will roll out the vaccine as early as possible.<br />&nbsp;</p><p>"Currently, we have 20 million doses. We are aiming to achieve 700 million doses capacity in four facilities -- three in Hyderabad and one in Bengaluru. We are encountering so many problems including related to logistics."<br />&nbsp;</p><p>The Biotech MD also confirmed that the cost of the vaccine may be a little higher in the beginning. He, however, said that the price will be controlled by the market as the scale of production increases.</p>

<p>The Biotech MD said that the company will roll out the vaccine as early as possible.<br />&nbsp;</p><p>"Currently, we have 20 million doses. We are aiming to achieve 700 million doses capacity in four facilities -- three in Hyderabad and one in Bengaluru. We are encountering so many problems including related to logistics."<br />&nbsp;</p><p>The Biotech MD also confirmed that the cost of the vaccine may be a little higher in the beginning. He, however, said that the price will be controlled by the market as the scale of production increases.</p>

The Biotech MD said that the company will roll out the vaccine as early as possible.
 

"Currently, we have 20 million doses. We are aiming to achieve 700 million doses capacity in four facilities -- three in Hyderabad and one in Bengaluru. We are encountering so many problems including related to logistics."
 

The Biotech MD also confirmed that the cost of the vaccine may be a little higher in the beginning. He, however, said that the price will be controlled by the market as the scale of production increases.

About the Author

AN
Asianet Newsable English
Latest Videos
Recommended Stories
Recommended image1
Mumbai woman and lover slit husband's throat, ride body on scooty, dump it; Arrested
Recommended image2
Winter grips Jammu and Kashmir: Freezing temperatures, snowfall hit Srinagar; Winter festivities draw tourists
Recommended image3
Delhi court denies bail to alleged drug syndicate kingpin Waseem Shaikh
Recommended image4
SC seeks Centre, ECI reply on plea for lifetime ban on convicted politicians
Recommended image5
J&K: Security forces recover AK rifles, ammo in Kupwara anti-terror operation
News
Breaking News TodayLatest News TodayIndia NewsWorld NewsKarnataka NewsKerala NewsIndian Defence NewsBengaluru News
Entertainment
Entertainment NewsOTT ReleaseBigg BossMovie ReviewsBox Office Collection
Sports
Sports NewsCricket NewsFootball NewsWWE NewsOther Sports
Lifestyle
Lifestyle NewsFood and RecipesHealth NewsAstrologyCareer NewsWeb Stories
Business
Business newsShare Market NewsGold PriceDA Hike8th Pay CommissionTechnology NewsAutomobile News
Weather
WeatherKolkata WeatherChennai WeatherBengaluru Weather
Asianet
Follow us on
  • Facebook
  • Twitter
  • whatsapp
  • YT video
  • insta
  • Download on Android
  • Download on IOS
  • About Website
  • Terms of Use
  • Privacy Policy
  • CSAM Policy
  • Complaint Redressal - Website
  • Compliance Report Digital
  • Investors
© Copyright 2025 Asianxt Digital Technologies Private Limited (Formerly known as Asianet News Media & Entertainment Private Limited) | All Rights Reserved